Will These Analyst Moves Affect Vertex Pharmaceuticals (VRTX) Stock Today?

NEW YORK (TheStreet) -- A pair of analysts took action on Vertex Pharmaceuticals (VRTX) on Wednesday.

HC Wainwright downgraded Vertex to "neutral" from "buy" and set an $85 price target. The firm said the company's 809 drug still has scientific risks.

UBS, on the other hand, increased its price target to $115 and set a "buy" rating. The firm said price, heterozygotes and takeout potential are all drivers of upside.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 0.45% to $93.11 in pre-market trading on Wednesday.

VRTX Chart

VRTX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants